Credit and interest ratesnegative · 2 filings
“We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc.”10-K · Mar 5, 2026 ↗
Nutex Health Inc.
NUTX
Market read
Nutex Health Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 0 directly disclosed connections are confirming.
Company-2.0% todayVolume comparison unavailable
Market group0 of 4 activeHealthcare Tech Solutions · unavailable
Disclosed network0 of 4 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- NUTX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if NUTX's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 0 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- NUTX's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements46
Verified relationships0
Evidence supporting the case
- Latest annual revenue changed +82.4% year over year.
- Operating margin changed +4.3 percentage points in the latest annual period.
- Operating cash flow covered net income at 3.51x in the latest annual period.
Evidence challenging the case
- Net margin changed -2.8 percentage points in the latest annual period.
- Diluted shares increased 23.0% in the latest annual period.
Questions before a position
- P/E is 28% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 10, 2026
194.966m+76.5%12m+117.2%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$331.5M+21.0%$0.22+2.4%
2022-12-31$219.3M-33.9%$-100.36—
2023-12-31$247.6M+12.9%$-10.39+4.2%
2024-12-31$479.9M+93.8%$9.69+24.6%
2025-12-31$875.3M+82.4%$10.48+23.0%
What management says matters
Persistent and emerging business drivers
Demand and volumepositive · 1 filings
“We expect that competition will continue to increase as a result of consolidation in the healthcare industry and increased demand for its services.”10-K · Mar 5, 2026 ↗
Macroeconomic conditionspositive · 1 filings
“Federal expenditure for healthcare increased by 5.5% due to the initial impacts of the Inflation Reduction Act on federal Medicare spending and faster spending growth for Medicare hospital and physician spending, while private health insurance spending increa…”10-K · Mar 5, 2026 ↗
Restructuring and cost reductionsnegative · 1 filings
“77 Table of Contents Due to the closure of a facility, we recorded an impairment loss of $ 0.7 million for the year ended December 31, 2023 as the carrying value of the facility’s license was greater than the license’s fair value.”10-K · Mar 5, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 1.5× · EV/sales 1.3×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
194.96-2.0% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for NUTX. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for NUTX. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind NUTX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NUTX is currently a Early Follower in the organic co-movement group Healthcare Tech Solutions. This group is discovered from market behaviour rather than assigned from an industry taxonomy. No verified filing-linked names are available yet.
This group is retained as the last observed read for NUTX; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.